Beth mae “Clir” yn ei olygu?
Nid yw'r anifail yn cario'r treiglad. Ni fydd yn datblygu'r afiechyd ac ni fydd yn ei drosglwyddo.
Canine Leukocyte Adhesion Deficiency Type III (CLAD3) is a rare genetic disorder affecting a dog’s immune system, leading to severe infections and poor wound healing. A DNA test for CLAD3 helps identify carriers and affected dogs, enabling responsible breeding decisions to prevent the spread of this condition. Early detection through genetic testing is crucial for managing the health of at-risk breeds. By using a reliable CLAD3 DNA test, breeders and veterinarians can improve canine health outcomes and reduce the incidence of this immune deficiency. Protect your dog’s future with accurate genetic screening for CLAD3 today. Stay informed and ensure your dog’s well-being with advanced DNA testing options.
Canine Leukocyte Adhesion Deficiency Type III (CLAD3) is a rare genetic disorder affecting a dog’s immune system. It impairs the ability of white blood cells to adhere and migrate to infection sites, leading to severe and recurrent infections. A DNA test can identify carriers and affected dogs by detecting mutations responsible for CLAD3. Early diagnosis through testing helps breeders make informed decisions to reduce the spread of this condition. Managing affected dogs requires veterinary care to address infections and support immune function.
Mae'r prawf DNA hwn wedi'i gynnwys gan ddechrau o'n pecyn Basic - ac mae hefyd yn rhan o'r pecynnau Basic, Standard, Advanced, Complete.
Gweld Pecynnau Prawf DNA →Canine Leukocyte Adhesion Deficiency Type III (CLAD3) is a genetic disorder that affects the immune system of dogs. This condition is characterized by a defect in the leukocyte adhesion process, which is critical for the proper functioning of the immune system. The deficiency disrupts the ability of white blood cells, or leukocytes, to adhere to blood vessel walls, preventing them from migrating to sites of infection or inflammation. As a result, affected dogs are more susceptible to infections and may experience chronic health issues.
Dogs with CLAD3 typically exhibit a range of clinical symptoms that are indicative of a compromised immune system. Common signs include recurrent infections, poor wound healing, and an increased frequency of inflammatory conditions. Affected dogs may also present with symptoms such as lethargy, fever, and swelling due to the inability of immune cells to effectively respond to pathogens.
The underlying cause of CLAD3 lies in a mutation within specific genes responsible for the production of adhesion molecules on leukocytes. These molecules are essential for the leukocyte's ability to stick to and traverse the endothelial cells lining blood vessels. When this adhesion process is impaired, the immune response is significantly weakened, leading to the clinical manifestations associated with the condition. This genetic mutation can lead to lifelong health challenges for affected dogs.
Diagnosis of Canine Leukocyte Adhesion Deficiency Type III involves genetic testing to identify the specific mutation responsible for the condition. A DNA test can confirm the presence of the mutation, allowing for an accurate diagnosis. This diagnostic tool is particularly valuable for breeders and veterinarians, as it helps identify at-risk individuals and informs breeding decisions to reduce the prevalence of the disorder within certain populations.
While there is currently no cure for CLAD3, management of affected dogs focuses on supporting their immune system and minimizing the risk of infections. This may include regular veterinary check-ups, prompt treatment of infections, and maintaining a clean environment to reduce exposure to pathogens. Additionally, owners may need to monitor their dogs closely for any signs of illness and seek veterinary care as needed.
Canine Leukocyte Adhesion Deficiency Type III is a serious genetic disorder that poses significant challenges for affected dogs due to their compromised immune function. Understanding the condition, recognizing its symptoms, and pursuing genetic testing are crucial steps in managing the health of dogs at risk. By raising awareness and educating dog owners and breeders, it is possible to mitigate the impact of this condition on canine health.
Nid yw'r anifail yn cario'r treiglad. Ni fydd yn datblygu'r afiechyd ac ni fydd yn ei drosglwyddo.
Mae'r anifail yn gyffredinol iach ond gall drosglwyddo'r treiglad iddo epil.
Mae'n cario dau gopi treigledig. Disgwylir arwyddion clinigol yn dibynnu ar y clefyd. Ni ddylid ei fridio.
Mae rhai afiechydon yn gysylltiedig â rhyw, felly mae eu mynegiant yn amrywio yn dibynnu ar y rhyw anifail.
This DNA test detects the mutation associated with Canine Leukocyte Adhesion Deficiency Type Iii (CLAD3) in order to identify clear, carrier, or at-risk animals.
Mae profion DNA yn helpu bridwyr i gynllunio paru mwy diogel a lleihau'r risg o drosglwyddo'r mwtaniad i'r epil.
Y modd etifeddu a adroddwyd ar gyfer y prawf hwn yw Autosomal Recessive.
This test analyses the mutation FERMT3 c.1349_1350insAAGACGGCTGCC.
Ddim o reidrwydd. Mae dehongliad yn dibynnu ar y patrwm etifeddiaeth a'r genoteip canlyniadol.
Boudreaux M K, Wardrop K J, Kiklevich V, Felsburg P, Snekvik K. A mutation in the canine Kindlin-3 gene associated with increased bleeding risk and susceptibility to infections. Thromb Haemost. 2010 Feb;103(2):475-7. doi: 10.1160/TH09-09-0571. Epub 2009 Nov 13.
Eich preifatrwydd, eich dewis
Rydym yn defnyddio cwcis hanfodol i redeg y wefan. Mae cwcis dewisol (fel darparwyr cynnwys wedi'u mewnosod) wedi'u hanalluogi yn ddiofyn a dim ond os ydych chi'n cytuno y cânt eu galluogi. Gallwch newid eich dewis unrhyw bryd gan ddefnyddio'r botwm "Cwcis".
Yn ofynnol ar gyfer nodweddion craidd a diogelwch. Wedi'i alluogi bob amser.
Yn gwella nodweddion fel arbed dewis neu fewnosod nad yw'n hysbysebu.
Mae'n ein helpu i ddeall defnydd y safle. Wedi'i analluogi yn ddiofyn.
Hysbysebu/olrhain ar draws safleoedd (rhai fideo/mapiau wedi'u mewnosod). Wedi'i analluogi yn ddiofyn.